Denali Therapeutics (DNLI) vs Relay Therapeutics (RLAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Relay Therapeutics (RLAY) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 207.9% versus a gain of 28.6%. Over five years, RLAY leads with a -47.4% price change compared with -57.9% for DNLI. Relay Therapeutics is the larger company by market cap ($3.80 billion vs $2.97 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNLI | RLAY |
|---|---|---|
| Share price | $18.56 | $17.35 |
| Market cap | $2.97B | $3.80B |
| 1-day change | -3.13% | -3.34% |
| YTD return | +16.05% | +112.17% |
| 1-year return | +28.59% | +207.89% |
| 5-year return | -57.95% | -47.38% |
| EPS (TTM) | $-2.84 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $15.36M |
| Revenue growth (YoY) | — | +53.44% |
| Net income (latest FY) | $-512.54M | $-276.48M |
| Operating margin | — | -1971.59% |
| Net margin | — | -1800.58% |
| 52-week high | $27.30 | $21.27 |
| 52-week low | $13.75 | $5.85 |
| Distance from 52-week high | -32.01% | -18.43% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +94.29% | +58.96% |
| Average volume | 1.61M | 2.80M |
| Shares outstanding | 159.85M | 219.14M |
| Employees | 503 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLAY has outperformed DNLI by 179.3 percentage points over the past year.
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
About Relay Therapeutics
RLAY stock →Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 202 employees
DNLI vs RLAY FAQ
Which is bigger, Denali Therapeutics or Relay Therapeutics?
Relay Therapeutics (RLAY) is larger, with a market capitalization of $3.80B compared with $2.97B for Denali Therapeutics (DNLI).
Which stock has performed better over the past year, DNLI or RLAY?
RLAY returned +207.89% over the past 12 months, compared with +28.59% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Denali Therapeutics and Relay Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.